Disseminate Recurrent Folliculitis and Hidradenitis Suppurativa Are Associated Conditions: Results From a Retrospective Study of 131 Patients With Down Syndrome and a Cohort of 12,351 Pediatric Controls
Keywords:
hidradinitis suppurativa, folliculitis, Down syndrome, pediatric, hair follicle diseaseAbstract
Background: Hidradenitis suppurativa (HS) is a chronic, inflammatory, recurrent skin disease of the pilosebaceous unit characterized by protean manifestations. Several studies have found an increased incidence and earlier presentation of this disease in patients carrying trisomy 21. Patients with Down syndrome (DS) have a higher risk of developing a wide range of cutaneous manifestations, including HS and chronic folliculitis. Recently, disseminate recurrent folliculitis (DRF) has been reported as an atypical monosymptomatic feature of HS at its onset.
Objective: To assess the prevalence of HS and DRF by comparing a cohort of patients carrying trisomy 21 vs pediatric controls.
Methods: A retrospective 2-year monocentric clinical study was performed by collecting clinical data of 131 patients with DS, aged 4-36 years, followed at the Dermatology Unit and Down Syndrome Regional Center of Bologna University. Data were matched with those coming from 12,351 pediatric controls.
Results: In DS patients, DRF and HS showed a prevalence of, respectively, 6.8% and 24.4%, while 5.3% of patients presented both diseases. In the control group the prevalence for HS+ and DRF+ was 0.5% and 1.2%, respectively, with a 0.14% of overlap cases. The association between HS and DRF proved to be statistically significant in both groups (P < 0.05). In the DS cohort the mean age of symptoms onset was 15.67 (SD: 2.29) years for HS and 13.11 (SD: 4.93) years for DRF. Buttocks were the most frequently affected body area for DRF followed by the inguinocrural area, while in HS buttocks were less frequently involved than groins and upper thighs.
Conclusions: Because of the later onset of HS, patients with DRF at an early age should be monitored for the possible onset of HS in the apocrine-bearing areas.
References
Madan V, Williams J, Lear JT. Dermatological manifestations of Down's syndrome. Clin Exp Dermatol. 2006;31(5):623-629.
Schepis C, Barone C, Siragusa M, Pettinato R, Romano C. An updated survey on skin conditions in Down syndrome. Dermatology 2002;205(3):234-238.
Luelmo-Aguilar J, Santandreu MS. Folliculitis: recognition and management. Am J Clin Dermatol. 2004;5(5):301-310.
Schepis C, Siragusa M. Secondary anetoderma in people with Down's syndrome. Acta Derm Venereol. 1999;79(3):245.
Kavanagh GM, Leeming JP, Marshman GM, Reynolds NJ, Burton JL. Folliculitis in Down's syndrome. Br J Dermatol. 1993;129(6):696-699.
Finn OA, Grant PW, McCallum DI, Raffle EJ. A singular dermatosis of Mongols. Arch Dermatol. 1978;114(10):1493–1494.
Revuz J. Disseminate recurrent folliculitis as the presenting picture of hidradenitis suppurativa. Ann Dermatol Venereol. 2017;144(11):715-718.
Garg A, Strunk A, Midura M, Papagermanos V, Pomerantz H. Prevalence of hidradenitis suppurativa among patients with Down syndrome: a population-based cross-sectional analysis. Br J Dermatol. 2018;178(3):697-703.
Wang JF, Orlow SJ. Keratosis pilaris and its subtypes: associations, new molecular and pharmacologic etiologies, and therapeutic options. Am J Clin Dermatol. 2018;19(5):733-757.
Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619-644.
Hurley HJ. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach. In: Roenigk RK, Roenigk HH, eds. Dermatologic Surgery. New York: Marcel Dekker; 1989:729-739.
Plewig G, Kligman AM. Acne conglobata. In: Acne. Berlin, Heidelberg: Springer; 1975:168-203.
Lookingbill DP. Yield from a complete skin examination: findings in 1157 new dermatology patients. J Am Acad Dermatol. 1988;18(1 Pt 1):31-37.
Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol. 1996;35(2 Pt 2):191-194.
Cosmatos I, Matcho A, Weinstein R, Montgomery MO, Stang P. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol. 2013;68(3):412-419.
Denny G, Anadkat MJ. Hidradenitis suppurativa (HS) and Down syndrome (DS): increased prevalence and a younger age of hidradenitis symptom onset. J Am Acad Dermatol. 2016;75(3):632-634.
Liy-Wong C, Pope E, Lara-Corrales. Hidradenitis suppurativa in the pediatric population. J Am Acad Dermatol. 2015;73(5 Suppl 1):S36-S41.
Palmer RA, Keefe M. Early-onset hidradenitis suppurativa. Clin Exp Dermatol. 2001;26(6):501-503.
Deckers IE, van der Zee HH, Boer J, Prens EP. Correlation of early-onset hidradenitis suppurativa with stronger genetic susceptibility and more widespread involvement. J Am Acad Dermatol. 2015;72(3):485-488.
Scheinfeld N. Hidradenitis suppurativa in prepubescent and pubescent children. Clin Dermatol. 2015;33(3):316-319.
Ebling FJG. Hidradenitis suppurativa: an androgen-dependent disorder. Br J Dermatol. 1986;115:259-262.
Garg A, Kirby JS, Lavian J, Lin G, Strunk A. Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. JAMA Dermatol. 2017;153(8):760-764.
Canoui-Poitrine F, Le Thuaut A, Revuz JE, et al. Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study. J Invest Dermatol. 2013;133(6):1506-1511.
Karousou E, Stachtea X, Moretto P, et al. New insights into the pathobiology of Down syndrome—hyaluronan synthase-2 overexpression is regulated by collagen VI α2 chain. FEBS J. 2013;280(10):2418-2430.
Quarello E, Guimiot F, Moalic JM, Shnoneau M, Ville Y, Delezoide AL. Quantitative evaluation of collagen type VI and SOD gene expression in the nuchal skin of human fetuses with trisomy 21. Prenat Diagn. 2007;27(10):926-931.
Theocharidis G, Drymoussi Z, Kao AP, et al. Type VI collagen regulates dermal matrix assembly and fibroblast motility. J Invest Dermatol. 2016;136(1):74-83.
Giovanardi G, Chiricozzi A, Bianchi L, et al. Hidradenitis suppurativa associated with Down syndrome is characterized by early age at diagnosis. Dermatology. 2018;234(1-2):66-70.
O' Shea M, O' Shea C, Gibson L, Leo J, Carty C. The prevalence of obesity in children and young people with Down syndrome. J Appl Res Intellect Disabil. 2018;31(6):1225-1229.
Melnik BC, Plewig G. Impaired Notch signalling: the unifying mechanism explaining the pathogenesis of hidradenitis suppurativa (acne inversa). Br J Dermatol. 2013;168(4):876-878.
Kusters MA, Verstegen RH, Gemen EF, de Vries E. Intrinsic defect of the immune system in children with Down syndrome: a review. Clin Exp Immunol. 2009;156(2):189-193.
Highet AS, Warren RE, Weeks AJ. Bacteriology and antibiotic treatment of perineal suppurative hidradenitis. Arch Dermatol. 1988;124(7):1047–1051.
Melnik BC, Plewig G. Impaired Notch-MKP-1 signalling in hidradenitis suppurativa: an approach to pathogenesis by evidence from translational biology. Exp Dermatol. 2013;22(3):172-177.
Schlapbach C, Hänni T, Yawalkar N, Hunger RE. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2011;65(4):790-798.
Berezovska O, Jack C, Deng A, Gastineau N, Rebeck GW, Hyman BT. Notch1 and amyloid precursor protein are competitive substrates for presenilin1-dependent gamma-secretase cleavage. J Biol Chem. 2001;276(32):30018-30023.
Blok J, Jonkman M, Horváth B. The possible association of hidradenitis suppurativa and Down syndrome: is increased amyloid precursor protein expression resulting in impaired Notch signalling the missing link? Br J Dermatol. 2014;170(6):1375-1377.
Herzog V, Kirfel G, Siemes C, Schmitz A. Biological roles of APP in the epidermis. Eur J Cell Biol. 2004;83(11-12):613-624.
Garg A, Lavian J, Lin G, Strunk A, Alloo A. Incidence of hidradenitis suppurativa in the United States: a sex- and age-adjusted population analysis. J Am Acad Dermatol. 2017;77(1):118-122.
Vlassova N, Kuhn D, Okoye GA. Hidradenitis suppurativa disproportionately affects African Americans: a single-center retrospective analysis. Acta Derm Venereol. 2015;95(8):990-991.
Gasparic J, Theut Riis P, Jemec GB. Recognizing syndromic hidradenitis suppurativa: a review of the literature. J Eur Acad Dermatol Venereol. 2017;31(11):1809-1816.
Wortsman X, Moreno C, Soto R, Arellano J, Pezo C, Wortsman J. Ultrasound in-depth characterization and staging of hidradenitis suppurativa. Dermatol Surg. 2013;39(12):1835–1842.
Published
Issue
Section
License
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
